Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 21Active not recruiting 14Recruiting 11Terminated 7Unknown 3Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 291Drug Therapy 277Bevacizumab 249apatinib 247camrelizumab 219Etoposide 201Irinotecan 183Doxorubicin 181Leucovorin 164Dexamethasone 161pembrolizumab 155Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × luprolide acetate gel depot × Clear all
NCT04239599 2022-09-29

RCT-PHART2

Sunnybrook Health Sciences Centre

Phase NA Unknown
178 enrolled
Genitourinary

Prostatic Neoplasms

NCT03380806 2020-06-04

PBS

Juravinski Cancer Center

Phase 2 Unknown
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT00452556 2014-03-19

The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

Nova Scotia Cancer Centre

Phase 2 Unknown
86 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡